Back to first-pass browser

First-pass extracted concept

lipid self-assembling nanoparticle

Candidate: toolkit itemType: delivery harness1 source documents5 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

mRNA-SANP, SANP

Extracted Explainers

What the tool is doing

SANP is a lipid self-assembling nanoparticle technology used to formulate and deliver mRNA. In this paper it is presented as a platform for reporter-gene delivery and SARS-CoV-2 spike mRNA vaccination in mice.

Source 1DOIPubMed

Resources required

The platform requires mRNA cargo and formulation components that are mixed immediately before use. The abstract also describes IM and IV administration and serum/plasma characterization assays.

Source 1DOIPubMed

What problem it solves

The paper positions SANPs as a way to improve storage and transport stability for mRNA therapeutics by avoiding frozen storage. It also provides a delivery vehicle for in vivo mRNA expression and vaccination.

Source 1DOIPubMed

What it does not solve

The abstract does not establish human clinical performance or long-term comparative efficacy versus standard mRNA-LNPs. Exact formulation composition and manufacturing details are not provided in the abstract.

Source 1DOIPubMed

Alternatives

The abstract contrasts SANPs with conventional mRNA-LNP formulations that require low-temperature storage. No specific named comparator formulation is given in the abstract.

Source 1DOIPubMed

Evidence Snippets

Here, we introduce a lipid self-assembling nanoparticle (SANP) technology to address the stability challenges of mRNA-based therapeutics.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1immunogenicitysupports2026Source 1DOIPubMed

mRNA-SANPs encoding SARS-CoV-2 spike protein elicited a significant immune response in mice after both IM and IV administration.

Quoted textsource-backed
Finally, mRNA-SANPs encoding the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein elicited a significant immune response in mice following both IM and IV administration.
Claim 2in vivo expressionsupports2026Source 1DOIPubMed

IM and IV administration of reporter-gene mRNA-SANPs in mice produced high levels of transgene expression without observed renal or hepatic toxicity and without release of pro-inflammatory cytokines.

Quoted textsource-backed
Intramuscular (IM) and intravenous (IV) administration of mRNA-SANPs encoding a reporter gene in mice resulted in high levels of transgene expression, with no observed renal or hepatic toxicity and no release of pro-inflammatory cytokines.
Claim 3mechanistic correlationsupports2026Source 1DOIPubMed

Protein fingerprint analysis of mRNA-SANPs in serum identified specific nanoparticle-protein interactions that correlated with in vivo biodistribution.

Quoted textsource-backed
Additionally, protein fingerprint analysis of mRNA-SANPs in serum identified specific nanoparticle-protein interactions that correlated with in vivo biodistribution.
Claim 4physicochemical propertysupports2026Source 1DOIPubMed

mRNA-SANPs exhibit sub-200 nm particle size, high mRNA encapsulation efficiency, colloidal stability after assembly and in human plasma, and low hemolytic activity.

Quoted textsource-backed
SANPs loaded with mRNA (mRNA-SANPs) exhibited a sub-200 nm size, high mRNA encapsulation efficiency, colloidal stability post-assembly and in human plasma, and low hemolytic activity.
Claim 5stability advantagesupports2026Source 1DOIPubMed

SANP technology is introduced to address stability challenges of mRNA-based therapeutics and allows mRNA vaccines to be stored and transported at 4°C without freezing by mixing components immediately before use.

Quoted textsource-backed
SANP formulations can be prepared by simply mixing the components immediately before use, allowing mRNA vaccines to be stored and transported at 4°C without freezing, thereby enhancing their stability.